eOphtha

Menu

 


Acetazolamide | Acetylcholine | Acyclovir | Adalimumab | Amikacin | Amphotericin B | Ampicillin | Apraclonidine| Atropine | Azathioprine | Azelastine | Betaxolol | Bevacizumab| Biologicals | Brimonidine | Brinzolamide  | Bupivacaine | Capsofungin  | Cefazolin | Cidofovir | Ciprofloxacin | Clotrimazole | Corticosteroids | Cyclopentolate | Cyclosporine A | Cyclophosphamide | Daclizumab | Dorzolamide | EDTA | Epinephrine | Etanercept| Erythromycin | Famciclovir | Foscarnet | Fluconazole | Fluorescein Sodium | Fluorometholone | 5-Fluorouracil | Flurbiprofen   | Ganciclovir | Gatifloxacin | Gentamicin | Glycerin | Homatropine | Hydroxypropyl | Idoxurudine | Indocyanine Green | Infliximab | Interferon alpha | Itraconazole | Ketoconazole | Ketorolac | Latanoprost | Leflunomide | Lidocaine | Loteprednol | Mannitol  | Methotrexate | Methylene Blue | Mitomycin | Moxifloxacin | Mycophenolate Mofetil | Naphazoline | Natamycin | Nedocromil Sodium | Neomycin Sulfate | Ofloxacin | Olopatadine | Pegaptanib | Pilocarpine | Timolol | Valacyclovir | Valganciclovir | Vidarabine | Voriconazole

Adalimumab

It is an IgG monoclonal antibody to human necrosis factor. Adamilumab has an added advantage over infliximab as it is a fully humanised antibody.It has been found useful in chronic uveitis in children & Behcet’s Disease. Vazquez-Cobian et al treated 14 patients of childhood uveitis with adalimumab,of which 13 showed significant decrease in ocular inflammation.


• Adalimumab has been approved by the FDA for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, moderate to severe chronic psoriasis and juvenile idiopathic arthritis in 2008
• It has a half-life of 10-20 days.
• It is marketed in both preloaded 0.8 ml syringes and also in preloaded pen devices (called Humira Pen), both injected subcutaneously, typically by the patient at home.


 

The usual FDA approved dosage for treating rheumatoid arthritis is 40 mg injected subcutaneously every 2 weeks. However it may be sufficient to treat intraocular inflammation in little lower doses.

Though initial reports are seems to be promising for the use of adalimumab and lower incidence of side effects, such as injection site reaction and the formation of neutralizing antibodies, but prospective, randomized trials are needed to confirm the utility of the drug in the treatment of intraocular inflammation.

 


Biologicals
, TNF-alpha Blocker


Statutory Warning

Materials / Informations provided here are for educational purpose only ; and not to be used for medical advice, diagnosis or treatment